Company Overview and News
Shares of Apple (AAPL - Free Report) declined about 1% on Jun 8 thanks to reports that the tech giant is likely to ship fewer iPhones in the second half of 2018. Apple has reportedly told its supply chain to manufacture about 20% lesser (compared with 2017’s orders) components for iPhones slated to be unveiled in the second half of this year, per Nikkei. Apple is expected to launch three new iPhones this year, expected to be shipped in September.
VGT SOXX EWT IYW IFNNY CHJHF AAPL CHA IFNNF 0728 DLGNF TSM
While everyone has been focusing on the FANGs, the semiconductor stocks have been quietly dominating. The sector benchmark — the iShares PHLX Semiconductor ETF (NASDAQ:SOXX) –managed to clock in a whopping 41% return in 2017. That’s roughly double what the S&P 500 managed to put up last year.
SOXX TXN AMD INTC ON
Trade war fears between the United States and its trading partners have been rife since March. Trump’s announcement in early March that the United States will impose a 25% tariff on steel imports and a 10% tariff on aluminum imports first spooked the market.
LMT SOXX STZ.B FXG MDLZ STZ CARZ TSNU BOE XAR BA TSN HSY ITA
Turning a deaf ear tothe maxim — “sell in May and go away” — Wall Street held its head high in the month. The proverb is actually ingrained in the S&P 500’s awful historical run for the May-to-October period, but was hardly apt for recent years. The S&P 500 index was up 2.8% in the last one month (as of May 30, 2018) while the Dow Jones Industrial Average advanced 2.1% and the Nasdaq composite jumped 5.
SOXX SBIO ELY EWI EWZS XHE AGT
Designed to provide broad exposure to the Technology - Semiconductors segment of the U.S. equity market, the PowerShares Dynamic Semiconductors Portfolio (PSI - Free Report) is a passively managed exchange traded fund launched on 06/23/2005.
SOXX TXN FMAT MU FUTY INTC AKAM
If you're interested in broad exposure to the Technology - Semiconductors segment of the U.S. equity market, look no further than the PowerShares Dynamic Semiconductors Portfolio (PSI - Free Report) , a passively managed exchange traded fund launched on 06/23/2005.
SOXX TXN MU INTC CSIQ
After the closing bell yesterday, Nvidia (NVDA - Free Report) reported stronger-than-expected first-quarter fiscal 2019 results. The company beat the Zacks Consensus Estimate for both the top and the bottom line and issued an upbeat guidance buoyed by strong demand for gaming and cloud services. However, a steep slowdown in demand from cryptocurrency miners has dampened investors’ mood. As such, shares of NVDA pulled back 2% in aftermarket hours from the record highs reached in the regular trading session (read: Should You Snap Up Downtrodden Semiconductor ETFs Now?).
SOXX NVDA FNG
As everyone who follows the industry knows, everything is all about supply and demand. When demand is high and supply is low, chip prices are high and chipmakers have huge profit margins. Conversely, when demand is low and supply is high, chip prices are low and chipmakers have low profit margins.
SOXX BABA AMZN MU AAPL MSFT NVDA INTC BIDU SMH
Taiwan Semiconductor Manufacturing Co Ltd TSM hit the entire technology industry hard after the company reported Q1 results on Apr 19 before market open. The world’s biggest contract chipmaker, cut its full-year revenue target to the low end of its prior guidance of 10-15% thanks to “softer demand for smartphones and uncertainty in cryptocurrency mining market.”
SOXX STM NVDA ISRG VGT EWT IYW AMAT AAPL AVGO BRCM TSM
The semiconductor corner of the broad technology market was badly hit last week amid a spate of negative news from industry players like chipmaker Taiwan Semiconductor Manufacturing TSM and semiconductor-equipment supplier Lam Research LRCX. Taiwan Semiconductor reduced its target for sales growth in the global semiconductor industry this year to 5% from its prior outlook of 5-7% growth while Lam Research offered a disappointing outlook for chip-gear shipments for the rest of the year.
SWKS LRCX SOXX NINE TXN AMAT AAPL AVGO CRUS NVDA QCOM INTC
Shares of several major semiconductor industry stocks were down in early morning trading Wednesday after the latest quarterly earnings reports from equipment suppliers ASML Holding (ASML - Free Report) and Lam Research (LRCX - Free Report) caused hesitation.
LRCX SOXX TXN ASML AMAT
As bearish as I’ve been on Advanced Micro Devices, Inc. (NASDAQ:AMD), I can’t say I saw the recent decline in AMD stock coming. AMD stock dipped below $10 earlier this month, touching a 16-month low in the process.
SOXX MU AMD NVDA INTC
Chicago, IL – April 18, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include VanEck Vectors Semiconductor ETF (SMH - Free Report) , iShares PHLX Semiconductor ETF (SOXX - Free Report) , PowerShares Dynamic Semiconductor (PSI - Free Report) , SPDR S&P Semiconductor ETF (XSD - Free Report) and First Trust Nasdaq Semiconductor ETF (FTXL - Free Report) .
SOXX AZRE CRK MS.PRE USFD MS.PRF WCG MS.PRG NEP MS.PRA GOLF X MS.PRI MS.PRK AMAT XSD ADM MS TNET
Designed to provide broad exposure to the Technology ETFs category of the U.S. equity market, the SPDR S&P Semiconductor ETF (XSD - Free Report) is a smart beta exchange traded fund launched on 01/31/2006.
WFC WFCNP SOXX WFC.WS WFC.PRL WFC.PRJ WFC.PRT WFC.PRR WFC.PRQ SMTC WFC.PRP WFC.PRO MU WFC.PRN IPHI XSD WFC.PRY WFC.PRX WFC.PRW WFC.PRV
The PowerShares Dynamic Semiconductors Portfolio (PSI - Free Report) made its debut on 06/23/2005, and is a smart beta exchange traded fund that provides broad exposure to the Technology ETFs category of the U.S. equity market.
SOXX MU AMAT INTC
3h - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...
2018-06-11 - Asif
Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...
2018-06-11 - Asif
Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...
Silicon Investor Message Boards
This table lists all message boards related to SOXX / iShares PHLX Semiconductor ETF on message board site Silicon Investor.
|Iu0027m a booted Sox (or is it Soxx?) clown...|
as of ET